Our start up companies
The institute has established several companies to facilitate research translation and to promote collaboration. The institute continues to be involved in their strategic planning, research, operations and capital raising.
BACE Therapeutics Pty Ltd
A Australian biotechnology company focused on the development of small molecule inhibitors of b-secretase for the treatment of Alzheimer’s Disease. Culminating from a collaboration between the institute, the University of Melbourne and the Mental Health Research Institute of Victoria, BACE Therapeutics was founded in 2009 with an investment from the Medical Research Commercialsation Fund (MRCF).
An Australian publicly listed company (ASX: GBI) that develops and commercialises multiplexed molecular diagnostic tests, based upon its proprietary AmpaSandTM bead-based technology.
Genera's first product on sale is PapTypeTM, a highly competitive molecular diagnostic test for the simultaneous detection and genotyping of the 14 types human papillomavirus (HPV). The company has a number of other products in its development pipeline.
An Australian-based drug discovery and development company focused on the discovery, development and commercialisation of novel drugs against inflammation and anti-apoptosis targets.
ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with coeliac disease.
ImmusanT’s treatment is an immune tolerising therapy using a series of peptides which target the common genetic form of coeliac disease. This peptide-based immunotherapy is designed to tolerise the patient’s immune system to toxic gluten peptides.
Our research partnerships and collaborations
The institute has also played a central role in establishing several research collaborations to facilitate research translation and to promote collaboration.